Merck, Pfizer end patent feud over pneumococcal vaccines with royalty-centered settlement
A long-running patent battle between two pharma giants over their competing pneumococcal conjugate vaccines has come to an end.
Merck and Pfizer have reached a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
